ADC Therapeutics SA EBITDA 2019-2023 | ADCT
ADC Therapeutics SA ebitda from 2019 to 2023. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
ADC Therapeutics SA Annual EBITDA
(Millions of US $) |
| 2022 |
$-121 |
| 2021 |
$-259 |
| 2020 |
$-217 |
| 2019 |
$-118 |
| 2018 |
$-125 |
ADC Therapeutics SA Quarterly EBITDA
(Millions of US $) |
| 2023-03-31 |
$-51 |
| 2022-12-31 |
$-10 |
| 2022-09-30 |
$-3 |
| 2022-06-30 |
$-69 |
| 2022-03-31 |
$-40 |
| 2021-12-31 |
$-62 |
| 2021-09-30 |
$-57 |
| 2021-06-30 |
$-70 |
| 2021-03-31 |
$-70 |
| 2020-12-31 |
$-77 |
| 2020-09-30 |
$-52 |
| 2020-06-30 |
$-45 |
| 2020-03-31 |
$-43 |
| 2019-12-31 |
|
| 2019-09-30 |
$-32 |
| 2019-06-30 |
$-24 |
| 2018-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.175B |
$0.210B |
|
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
|
